

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/004696 A1

(51) International Patent Classification⁷: **A61K 9/50**

(74) Agent: **BURFORD, Anthony, F.**; W.H. Beck, Greener & Co., 7 Stone Buildings, Lincoln's Inn, London WC2A 3SZ (GB).

(21) International Application Number:
PCT/GB2003/002911

(22) International Filing Date: 4 July 2003 (04.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0215656.0 5 July 2002 (05.07.2002) GB
0215657.8 5 July 2002 (05.07.2002) GB

(71) Applicant (for all designated States except US): **TEM-REL INC.** [—/GB]; 9 Myrtle Street, Douglas, Isle of Man IM1 1ED (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SPEIRS, Christopher, J.** [GB/GB]; 82 Lower Road, Fetcham, Leatherhead, Surrey KT22 9NG (GB). **MOIR, Peter** [GB/IE]; Kilminion, South Ballin Road, Dungarvan, Country Waterford (IE). **WILLIAMS, Richard** [GB/CH]; Andreas Heusler Strasse 8, CH- 4052 Basel (CH). **CLARK, Michael** [CA/GB]; 23 Suffolk Square, Cheltenham, Gloucestershire GL50 2EA (GB).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/004696 A1

(54) Title: CONTROLLED RELEASE COMPOSITION

(57) Abstract: An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and provide release of the active compound at various desired locations in the intestinal tract.

Controlled Release Composition

The present invention relates to the use of polymethacrylate materials, especially those whose
5 dissolution is pH dependent, and other coating materials whose dissolution is pH dependent, in the control of the release of an active compound in the intestinal tract. The present invention also relates to the use of prednisolone metasulphobenzoate (11,17-dihydroxy-21-[(3-
10 sulphobenzoyl)oxy]pregna-1,4-diene-3-20-dione) and pharmacologically acceptable salts, especially the sodium salt, in the treatment of inflammatory bowel disease and especially Crohn's disease.

15 In particular, it provides a solid pharmaceutical composition having two or more pluralities of active compound containing particles coated with a desired thickness of a polymethacrylate material, or other pH dissolution dependent coating material, to control the
20 release profile of the active compound such as prednisolone metasulphobenzoate. It also provides use of coating thickness of the polymethacrylate material, or other pH dissolution dependent coating material, to control the release profile of the active compound
25 through the intestinal tract.

Unless it is clear from the context that the free ester is intended, the term "prednisolone metasulphobenzoate" is used herein to include
30 pharmacologically acceptable salts of prednisolone metasulphobenzoate as well as the free ester.

It is desirable to be able to control the release of an active compound in the gastrointestinal tract. Some

conditions require local treatment in the intestine and if drugs for that purpose are absorbed systemically, problematic side effects can occur. In other situations, the acidic conditions in the stomach can degrade some
5 active compounds, especially peptides and proteins and a vehicle for their delivery to parts of the intestine from which they can be systemically absorbed or provide their therapeutic effect would be advantageous. Also, it may be advantageous for some active compounds, especially
10 peptides and proteins, to be administered to specific sites in the intestinal tract for systemic absorption, which may be at two or more different locations. Examples are compounds whose systemic absorption depend upon locating M cells or Peyer patches.

15

In other situations, it is simply desirable that an active compound be administered to the patient continually over a set period of time in order to maintain a desired plasma concentration of the active and
20 a controlled release oral composition provides a convenient and effective method of achieving this.

Some methods of controlling release of an active compound are known. For example, providing an enteric
25 coating on a tablet or capsule in order to enable its passage beyond the stomach before degrading in the small intestine is well known. Also, it is known to administer an active compound to a patient in a slow release matrix. Another known method is to make a derivative of the
30 active compound, for example a glucuronic acid derivative, which will not cleave until it comes into contact with an appropriate intestinal enzyme, for example glucuronidase, thereby releasing the active compound.

Of particular relevance to the provision of a controlled release formulation of active compounds are disorders of the intestinal tract, particularly those
5 that would benefit from a local effect and a pertinent example is inflammatory bowel disease (IBD).

Inflammatory bowel disease covers chronic non-specific inflammatory conditions of the gastrointestinal
10 tract, of which the two major forms are Crohn's disease and ulcerative colitis.

Crohn's disease may affect any part of the gastrointestinal tract although it frequently affects the
15 small intestine, especially the ileum and may also affect the jejunum and any part of the colon, including the rectum and especially the caecum. It is characterised by thickened areas of the gastrointestinal wall, with inflammation extending through all layers, deep
20 ulceration and fissuring of the mucosa. The affected areas are often interspersed with areas of relatively normal tissue.

Sulphasalazine has been used to treat cases of
25 Crohn's disease affecting the colon as has 5-aminosalicylic acid in an enteric coated or slow release form. Steroids are widely used to treat severe cases of inflammation of the colon, especially ulcerative colitis and Crohn's disease. Usually they are administered
30 orally or parenterally to provide a systemic effect, or rectally by enema to provide a topical effect. Relatively high doses of steroids are required to treat severe cases of inflammatory bowel disease. However, systemic absorption produces serious side effects and

although systemic absorption is lower with rectal administration, enemas treat only the lower colon and rectum and their use is inconvenient.

5 The most commonly used steroid in the oral treatment of inflammatory bowel disease is prednisolone (17,21-dihydroxypregna-1,4-diene-3,11,20-trione) in the form of the free alcohol or an ester thereof, usually the acetate. Daily doses of 15 to 60 mg (calculated as the
10 free alcohol) are required to treat severe cases of inflammatory bowel disease, but absorption at these doses is harmful. Accordingly, present treatment with prednisolone is limited in both dosage and duration of therapy.

15

Several methods and compositions for targeting or controlling the release of an active compound in the intestines have been proposed, often to treat inflammatory bowel disease and Crohn's disease.

20

US-A-4496553 relates to an oral pharmaceutical composition comprising 5-aminosalicylic acid (5-ASA) for the treatment of colitis ulcerosa or Crohn's disease. It discloses a slow-release tablet consisting of granules of
25 5-ASA coated with ethyl cellulose and compressed with microcrystalline cellulose granules, talc and sodium stearate. Tests with ileostomy patients showed that 50% of the active ingredient from the tablets is released in the small bowel. It states (in column 6, lines 15-22)
30 that release can be controlled by varying one or more of the particle size of the granulated active ingredient, the thickness and permeability of the coating, the active ingredient proper and the pH conditions within the coated particle.

EP-B-0097651 discloses a composition for selectively administering 5-aminosalicylic acid to the large intestine, comprising a solid oral dosage form containing
5 the active compound, with a coating of a 60 to 150 micrometer thick layer of an anionic polymer which is insoluble in gastric juice and in intestinal fluid below pH 7 but soluble in colonic intestinal juice, so that the dosage form remains intact until the colon.

10

EP-B-0572486 discloses an orally administrable pharmaceutical dosage form which comprises a plurality of granules of a drug, such as 5-aminosalicylic acid, coated with a material which dissolves in the intestine and
15 contained within a capsule which is also coated with a material which dissolves in the intestine. The composition is for selectively administering the drug to the intestine. It is stated that the granules are preferably contained within an enterically coated capsule
20 which releases the granules in the small intestine and that the granules are coated with a coating which remains substantially intact until they reach at least the ileum and preferably thereafter provide a sustained release of the drug through the colon.

25

EP-A-0772443 discloses a non-disintegratable solid enteric pharmaceutical composition comprising prednisolone metasulphobenzoate having relatively rapid dissolution at pH 6.5 from an excipient matrix, and
30 dosage forms containing pellets of the composition. The rapid dissolution is increased by the presence of a rheological modifying super-disintegrant in an amount of at least 5% by weight, but insufficient to cause disintegration of the composition. It is stated that the

composition may comprise a plurality of such pellets, which may be coated in an enteric coating such as cellulose acetate phthalate or, preferably, partly methyl esterified methacrylic acid polymers having a ratio of
5 free acid groups to ester groups of about 1:2, contained in a capsule that is enterically coated with a suitable coating material. The coating material on the pellets is preferably one that is insoluble in gastric juices and intestinal fluid below pH 7, but is soluble in lower
10 intestinal fluid. The enteric coating material of the capsule is chosen to protect the capsule during passage through the stomach. The composition is intended for use in the treatment of Crohn's disease.

15 EP-B-0502032 discloses a formulation for site specific release of an active compound in the colon for the treatment of diseases of the colon such as ulcerative colitis and Crohn's disease. The active may be, for example, prednisolone or 5-aminosalicylic acid among
20 others. The formulation comprises an active compound and amorphous amylose with an outer coating of cellulose or an acrylic polymer material. The active compound is preferably coated with glassy amylose, which tends not to degrade until it reaches the colon where it is attacked
25 by amylose cleaving enzymes provided by microbial flora normally present in the colon. The composition is further coated with a cellulose or acrylic polymer material, which enhances the delayed release property of the amylose coated composition. The rate of release of
30 the active compound from the composition once it reaches the colon may be controlled by varying the thickness of inner amylose coating provided. It states that it is also possible to vary the release in the colon by coating different particles of the active compound with amylose

of different thicknesses. Release characteristics can be further varied by drying, which affects pore size and permeability or by adding a fatty or waxy substance to retard penetration of water. It is preferred that the
5 cellulose or acrylic polymer outer coating material displays pH independent degradation.

WO-A-9921536 relates to a controlled release composition suitable for delivery of an active ingredient
10 to the colon. It discloses a composition which comprises 5-aminosalicylic acid spheres also containing microcrystalline cellulose and having diameters in the range 1.00 to 1.40 mm, which spheres are coated with a mixed solvent (water and an organic water miscible
15 solvent) amylose/ethyl cellulose composition, although the latter may instead be an acrylic polymer. The release profiles were examined for a range of amylose/ethyl cellulose ratios and coating thicknesses. It was found that coatings with a high proportion of
20 ethyl cellulose resulted in very little drug release due to the absence of continuous amylose channels through the coat surface to the core of the pellet, whereas a coating with a high proportion of amylose resulted in films whose structure was compromised. Accordingly, where higher
25 amylose concentrations were present in the coatings, a thicker coating was applied and the results showed that in such circumstances release of the active compound should not take place before the colon.

30 EP-A-0264989 discloses sustained release pharmaceutical formulations of rhein derivatives. In particular, it describes formulations intended to provide hematic levels of the drug for up to 24 hours from administration. As can be seen from Example 2 of this

reference, the general concept of coating particles with different thicknesses of a material (cellulose acetophthalate, in the Example) in order to release the drug compound at different rates so as to provide
5 sustained release over a predetermined time period is disclosed.

US-A-5529790 discloses pharmaceutical formulations which provide delayed and sustained release of a drug
10 from the formulation by means of a hydratable diffusion barrier coating. The delay is a consequence of the rate of hydration and the thickness of the coating and the sustained release results from the permeability and thickness of the coating. The diffusion barrier
15 preferably consists of a film-forming material that is insoluble in intestinal conditions and at least one further additive which controls the rate of hydration and permeability of the diffusion barrier. The preferred film-forming polymers are aqueous dispersions of fully
20 esterified acrylic resins (e.g. Eudragit NE30D), fully esterified acrylic resins containing quaternary amine side chains (e.g. Eudragit RS30D) or aqueous dispersions of ethyl cellulose. A preferred additive for controlling the rate of hydration and the permeability is magnesium
25 stearate. The drug (e.g. diltiazem hydrochloride) may be formulated as spherical microparticles having a diameter in the range 500-1500 μm and is preferably formulated in two batches of particles, a long delay batch having a low rate of hydration and low permeability and a short delay
30 batch having a relatively high rate of hydration and a high permeability, so that sustained release of the drug can be effected over an extended period of time. Dissolution studies were carried out on particles having different coating thicknesses.

US-A-4728512 discloses a pharmaceutical formulation comprising three groups of drug-releasing pellets presented in, for example, a capsule, of which each group
5 of pellets releases the drug at a different time in the patient's digestive system. In particular, it discloses a formulation where one group of pellets is uncoated and releases the drug immediately upon release of the pellets from the capsule, a second group of pellets which have a
10 pH-dependent coating (e.g. 20-30 wt% Eudragit S) and a third group of pellets which have a pH-independent coating, such as a dual-coat system where a time-dependent undercoat (e.g. hydroxypropyl methyl cellulose) is further coated with a hydratable diffusion barrier
15 coating (e.g. Eudragit E30D and metallic stearate). The formulation thereby consists of three drug release systems which provide drug release maximums during the periods 0-2 hours from administration, 2-6 hours from administration and 4-10 hours from administration
20 respectively. The formulation provides three doses of drug over a period of, for example, 12 hours, by releasing the drug on three occasions in an amount according to the relative quantity of each group of particles. The groups of particles are coated with
25 different thicknesses of coating materials and therefore the document discloses the general concept of using different groups of particles with different release properties to release the active compound at different locations in the intestinal tract (by virtue of the
30 different delay in releasing the drug from the second and third groups of pellets).

There is as yet no effective method or composition for controlling release of active compounds in the

intestine, which overcomes or accounts for the variation in pH and the rate of transit that occurs throughout the intestinal tract.

5 An improved method and composition for controlling release of an active compound such as prednisolone metasulphobenzoate to the intestinal tract would be desirable.

10 The inventors have now found that employing a pH dissolution dependent polymethacrylate material at different thicknesses on particles of prednisolone metasulphobenzoate surprisingly results in release of prednisolone metasulphobenzoate at different rates at the
15 same pH and in a controllable manner over a range of pH values. The thickness of the polymethacrylate coating employed may be chosen, depending upon the pH and the desired rate and location of release, to provide a controlled release profile of prednisolone
20 metasulphobenzoate. pH dissolution dependent coating materials such as polymethacrylates are usually employed to provide release of an active compound at a single location in the intestinal tract. To the best of our knowledge and belief, the use of different coating
25 thickness of pH dissolution dependent coating materials have not been used to provide continual or sustained release.

Accordingly, in a first aspect of the invention
30 there is provided an oral pharmaceutical composition comprising two or more pluralities of particles, said particles comprising prednisolone metasulphobenzoate, wherein the particles of each said plurality are coated with a different thickness of a polymethacrylate material

to those of the or each other plurality, whereby prednisolone metasulphobenzoate is released at different locations in the intestinal tract.

5 The inventors have also found that application of this technology surprisingly may be extended to compositions comprising other active compounds.

Accordingly, also in the first aspect of the
10 invention there is provided an oral pharmaceutical composition comprising two or more pluralities of particles, said particles comprising an active compound, wherein the particles of each said plurality are coated with a different thickness of a pH dissolution dependent
15 polymethacrylate material to those of the or each other plurality, whereby the active compound is released at different locations in the intestinal tract.

Without wishing to be bound by any particular
20 theory, the inventors believe that the graded release of the active compound from the compositions might be due to altered permeability of the coating rather than breakdown of the different thickness of coating. Observations indicate that the active compound would appear to
25 permeate out of the composition before disintegration of the composition occurs.

The following features may be applied to either the prednisolone metasulphobenzoate embodiment of the first
30 aspect of the present invention or to the more general embodiment.

The coating material may be any material that is used or is useful in the coating of oral pharmaceutical

dosage forms for delivery of an active compound to the intestine and is preferably a pH dissolution dependent cellulose derivative, such as cellulose acetate phthalate and hydroxypropyl methylcellulose acetate phthalate, or a
5 polymethacrylate material, which is preferably pH dissolution dependent.

The cellulose derivative is preferably selected from cellulose acetate phthalate, hydroxypropyl
10 methylcellulose, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate phthalate and other single or multiple ester and/or ether derivatives of cellulose whose dissolution is pH dependent.

15 By pH dissolution dependent coating material, it is meant to include those materials that, according to the current state of the art, are insoluble in gastric media until a certain pH is reached and those that give pH dependent release of a drug when used as a coating
20 material on oral pharmaceutical dosage forms.

The polymethacrylates which find particular utility in the present invention are anionic polymers of dimethylaminoethylmethacrylates, methacrylic acid and
25 methacrylic acid esters in varying ratios.

The polymethacrylates may be copolymers of acrylic acids (such as methacrylic acid) and acrylic acid esters (such as methyl methacrylate or ethyl methacrylate).
30 Preferably, the polymethacrylates used in accordance with the present invention are methacrylic acid copolymers, which are based upon methacrylic acid and various acrylic acid esters (such as ethyl acrylate or methyl methacrylate) or mixtures thereof. More preferably, one

or more copolymers of methacrylic acid and methyl methacrylate, preferably having a ratio of free carboxyl groups to ester groups of, for example, about 1:2 (sold under the registered Trade Mark EUDRAGIT S by Röhm Pharma GmbH of Darmstadt, Germany) and having a molecular weight of 135,000 or about 1:1 (available from Röhm Pharma GmbH under the registered Trade Mark EUDRAGIT L) or a mixture thereof is used.

10 Preferably, the present invention utilises those polymethacrylates whose dissolution is pH-dependent. By polymethacrylates whose dissolution is pH-dependent, it is meant to include those polymethacrylates that, according to the current state of the art, are insoluble
15 in gastric media until a certain pH is reached and those that give pH dependent release of a drug when used as a coating material, for example see The Handbook of Pharmaceutical Excipients, 3rd Edn., Edited by Arthur H. Kibbe (American Pharmaceutical Society and Pharmaceutical
20 Press, 2000). Preferably, the polymethacrylate material comprises a polymethacrylate that is insoluble in gastric media until a certain pH is reached and/or gives pH dependent release of a drug when used as a coating material, according to The Handbook of Pharmaceutical
25 Excipients whose monograph thereon on pages 401-406 is incorporated herein by reference.

Such polymethacrylates include copolymers of methacrylic acid and methyl methacrylate having a ratio
30 of free carboxyl groups to ester groups of about 1:2 (available as EUDRAGIT S from Röhm Pharma GmbH) or about 1:1 (available as EUDRAGIT L from Röhm Pharma GmbH) and a copolymer of methacrylic acid and ethyl acrylate having a ratio of free carboxyl groups to ester groups of about

1:1 (available under the registered Trade Mark EUDRAGIT L 30 D-55 or EUDRAGIT L 100-55 from Röhm Pharma GmbH).

More preferably, the polymethacrylate is one that is soluble at a pH greater than 5.5 and still more
5 preferably at greater than 6.

Preferably, the coating material coating the particles of each plurality of particles is the same as that coating those of the or each other plurality of
10 particles.

In one embodiment of the invention, the particles of each of the pluralities may be coated with a different thickness of the coating material chosen at increments to
15 provide a homogeneous release profile of the active compound along at least one selected portion of the intestinal tract or along the entire intestinal tract. The selected portion may be around, but preferably before and after, the ileo-caecal valve.

20

Preferably, the thickness of the coating material and the incremental differences are chosen to provide multi-site release of the active compound such that release is homogeneous through the intestine. It may be
25 desirable, for example when administering an active compound for the treatment of Crohn's disease, to provide homogeneous release of the active compound along the ileum and the colon and more particularly the ascending colon.

30

In this embodiment, the invention may provide homogeneous release of the active compound that has the advantage over conventional sustained release preparations in that the incremental differences in

thickness of the coating material, especially a polymethacrylate material, can be chosen to overcome the variations in pH and the varied rate of progression or transit of a capsule or tablet through the intestine.

5

In conventional sustained release preparations, the variation in the rate of progression through the intestinal tract may result in delivery of the active compound to certain parts of the intestine at a lower concentration than to other parts. Similarly, the variation in pH in different parts of the intestine tends to result in different rates of release from conventional sustained release preparations. This may result in a loss of effect.

15

In patients with inflammatory bowel disease, especially with active inflammation, the rate of transit through the intestine and the pH within the intestine are often abnormal. Conventional sustained release formulations which provide release of the active agent in a time or pH-dependent manner may not provide a predictable or effective delivery of the active agent to the target areas of the intestine. Such formulations can result in underdosing at certain sites or overdosing, "dose-dumping", at other sites.

25

In the present embodiment, such variations can be accounted for by, for example, coating particles of each plurality of particles with a chosen thickness of the coating material to provide multi-site release throughout the intestine, wherein the incremental differences in coating thickness between each plurality may vary. For example, in order to obtain homogeneous release to parts of the intestine through which there is a greater rate of

30

passage and to parts with a lesser rate of passage, the incremental differences in coating thickness for the pluralities of particles being delivered to the part of the intestine with a greater rate of passage will be smaller than to that with a lesser rate of passage, and/or the number of particles in the plurality of particles delivered to the part with greater rate of passage will be larger. Similarly, in order to provide homogeneous release to parts of the intestine with higher pH and with lower pH, a thicker coating should be provided on the particles that are intended to release the active compound to the part of the intestine with the higher pH, although this will depend upon its location within the intestine. In this way, the rate of release of the active compound may be controlled in relation to variations in pH or transit through the intestine, without being solely dependent upon either a specific pH being reached or a specific time having elapsed before release of the active compound.

20

Alternatively, the coating thickness on each of the pluralities may be chosen to effect release of the active compound at specified locations of the intestine. For example, each of the pluralities of particles may be coated with a different thickness of a coating material, whereby the active compound is released, for example, at locations around, but preferably before and after, the ileo-caecal valve.

30

Preferably, there are two pluralities of particles; one plurality in which the particles are coated with a thickness of the coating material so as to release the active compound at the distal ileum before the ileo-caecal valve and the other plurality in which the

particles are coated with a different thickness of the coating material so as to release the active compound at the proximal caecum, after the ileo-caecal valve.

Preferably the coating material is a polymethacrylate material, more preferably a methacrylic acid copolymer, and still more preferably a copolymer of methacrylic acid and methyl methacrylate, preferably having a ratio of free carboxyl groups to ester groups of about 1:2.

10 The coating on the particles may be of a thickness corresponding to a theoretical weight gain on coating of 15% for one of the pluralities and 20% weight gain for the other and preferably the number of particles in each plurality are present as a ratio of 15% weight gain
15 coated particles to 20% weight gain coated particles of 1:3.

20 In order to further control the release profile of the active compound through the intestine, particles from one plurality of particles may be coated with a different coating material to those of another plurality of particles. Particles of one plurality may also be of a different size to those of another plurality.

25 The present invention can be utilised, for example, to administer active compounds which have a therapeutic effect locally in the intestine, to administer active compounds of a high molecular weight for local or systemic action and for the administration of any active
30 compound for which controlled release through the intestinal tract would be of benefit, for example, active compounds whose systemic absorption depends upon location and rate of release in the intestine.

It is of particular utility to the provision of active compounds for local action at one or more sites in the intestinal tract. For example, in the treatment of inflammatory bowel disease and, in particular, Crohn's disease, where affected areas may be at various locations in the intestinal tract and the controlled delivery of an active compound to those areas without administering to unaffected areas minimises systemic absorption of the active compound and consequently any side effect that may result from systemic uptake.

In the administration of high molecular weight compounds, for example proteins or peptides, the present invention may be utilised to protect the active compound from degrading in the acidic conditions of the stomach and may, for example, provide delivery of the compound to areas of the intestine from which they may be absorbed or at which are located appropriate M-cells or Peyer's patches.

The invention is particularly applicable to the delivery of high molecular weight compounds in which the integrity of the tertiary structure is critical to the efficacy and safety of the compound. A particular advantage of the present invention is that the oral pharmaceutical composition may be prepared under gentle conditions relative to most pharmaceutical processes, whilst providing a desired release profile of the compound in the intestinal tract.

An example of a high molecular weight compound, which would benefit from formulation in a composition of the present invention is erythropoietin, a glycosylated protein hormone and haematopoietic growth factor, which

is considered useful in the management of anaemia in chronic renal failure among other conditions and has been investigated in the treatment of anaemia of inflammatory bowel disease as well as other normocytic-normochromic anaemias. Erythropoietin is conventionally administered subcutaneously or intravenously, although a tabletted form of erythropoietin has been disclosed (RU-A-2152206).

Other classes of high molecular weight compound which may benefit from the present invention include interferons, TNF antagonists and specific protein and polypeptide agonists and antagonists of the immune system, hormones, such as human growth hormone and cytokines and cytokine antagonists.

15

Other compounds and classes of compound whose administration may benefit from the present invention include analgesics and antipyretics; antibacterial and antiprotozoal agents, such as metronidazole and other nitroimidazole antibiotics and antibiotics active against anaerobic bacteria; clarithromycin and other macrolide antibiotics; gentamycin, ciprofloxacin, rifabutin and other such antibiotics active against infective organisms commonly associated with or causing disorders of the intestine; antiinflammatory agents such as, salicylates, for example 5-aminosalicylic acid, 4-aminosalicylic acid and derivatives, such as balsalazide, steroids, especially prednisolone metasulphobenzoate; probiotics and prebiotics which have been shown to influence the symptoms of inflammatory bowel disease and irritable bowel syndrome and recovery from antibiotic-associated diarrhoea; and pharmacologically active drug substances known to influence the symptoms of irritable bowel syndrome, for example those affecting the serotonergic

system and those active at the site of opiate receptors. α -amylase and paracetamol may also be administered using the composition of the present invention.

5 Other compounds which may benefit from the present invention include certain compounds that have toxic effects which limit their clinical usefulness, especially by causing local toxicity in specific areas of the gastrointestinal tract. Included among such compounds
10 are examples of antibiotics, bisphosphonates and antiinflammatory drugs. A particular example is metformin, which is intolerable to many patients due to adverse effects on the gastrointestinal tract. The present invention may be utilised to minimise the
15 concentration of the compound at the specific sites of toxicity and so allowing an effective therapeutic dose to be administered with a reduction in adverse events.

The preferred compounds for use in the present
20 invention are prednisolone metasulphobenzoate, 5-aminosalicylic acid, metronidazole, clarithromycin, metformin and erythropoietin.

In a preferred embodiment of the present invention,
25 the composition further comprises a capsule, preferably an enterically coated capsule, within which the pluralities of particles are contained. The capsule will usually be a soft, or preferably, hard gelatine capsule, although other capsules which will dissolve in the small
30 intestine may be used. The enteric coating will protect the capsule during its passage through the stomach. Any suitable enteric coating material which is soluble in the small intestine can be used. For example, cellulose acetate phthalate, hydroxypropyl methylcellulose

phthalate or initially ethyl cellulose followed by polyvinyl acetate phthalate may be used, but it is preferred to use an anionic polymer having an appropriate dissolution profile. The presently preferred polymers
5 are anionic carboxylic, that is polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the polymers should be acrylic polymers and the presently preferred polymers are copolymers of
10 methacrylic acid and methyl methacrylate in which the ratio of free acid groups to ester groups is about 1:1 (i.e. Eudragit L).

Alternatively, the particles may be compressed into
15 a tablet, which may be enterically coated.

The capsule (or other dosage form) coating can and usually will contain plasticiser and possibly other coating additives such as colouring agents, gloss
20 producers, talc and/or magnesium stearate as well known in the coating art. In particular, anionic carboxylic acrylic polymer coatings usually contain 10 to 25% by weight of a plasticiser, especially diethyl phthalate.

25 In a second aspect of the invention there is provided the use of the coating thickness of a pH dissolution dependent coating material on particles comprising an active compound to control the release profile of the active compound in the intestinal tract.
30 By pH dissolution dependent coating material, it is meant coating materials whose dissolution is dependent upon pH. For example, a polymethacrylate material which is insoluble at pH 2, but substantially soluble at greater

than pH 5.5 is a pH dissolution dependent polymethacrylate material.

In a third aspect of the present invention, there is
5 provided use of a coating material selected from

A. a polymethacrylate material; and

B. a pH dissolution dependent coating material

10

in the preparation of a medicament as described above for the treatment of disorders of the intestinal tract. Typically, the medicament will be for use in the treatment of Crohn's disease.

15

In a fourth aspect of the present invention, there is provided a method of treating a disorder of the intestinal tract of a patient, said method comprising administering to a patient an effective amount of an
20 active compound for treating that disorder in at least two pluralities of particles each coated with a different thickness of a coating material selected from

A. a polymethacrylate material; and

25

B. a pH dissolution dependent coating material

to release the active compound at locations in the intestinal tract at which symptoms of the disorder are
30 displayed and/or at which receptors substrate for the active compound are located.

The disorder may be any disorder of the intestinal tract and the active compound may be any compound

effective in treating that disorder, but preferably the disorder is any disorder mentioned above and preferably also the active compound is any of the active compounds mentioned above for treating the respective disorder.

- 5 Most preferably, the disorder is inflammatory bowel disease, especially Crohn's disease or anaemia associated with irritable bowel disease and more preferably still, the active compound is prednisolone metasulphobenzoate, 5-aminosalicylic acid, metronidazole, clarithromycin,
10 metformin or erythropoietin.

Antibiotics effective in the treatment of inflammatory bowel disease or infective disorders of the intestine are frequently toxic when absorbed and the
15 present invention may be applied to administer them to their sites of action in the intestine, achieving sufficient local concentrations whilst minimising systemic uptake. Of particular application to the present invention are toxic antibiotics, such as
20 gentamycin, particularly in patients predisposed to the toxic effects of such drugs such as those with renal dysfunction. Patients with chronic disorders of the intestine, for example Crohn's disease and pouchitis, requiring continued administration of certain
25 antibiotics, for example, metronidazole, over long periods are likely to benefit particularly from the present invention.

Other possible actives include cytotoxic agents such
30 as cyclophosphamide, cisplatin and other platinum drugs and vincristine and other vinca alkaloids; immunomodulators such as methotrexate, azathiaprine and cyclosporin; and anti-parasitic agents such as albenazole.

The particles used in the present invention are typically pellets or granules.

The particles according to the present invention may
5 be pellets having a diameter in the range 500 to 2500 μm , preferably 800 to 1700 μm , more preferably 800 to 1500 μm and still more preferably 1000-1500 μm . However, it should be appreciated that particles may have a diameter anywhere within the aforementioned ranges, or outwith,
10 and that a single dosage form according to the present invention may have particles of one or more diameter or range of diameters.

It should be appreciated that the actual coating
15 thickness for any particular weight gain of coating depends upon the size and weight of the particles.

Preferably the coating thickness according to the present invention is in the range 5% to 30%, more
20 preferably 10% to 25% and most preferably about 15% and about 20%.

Dosage forms in accordance with the present invention may contain particles which contain different
25 active compounds. For example, one plurality of particles may contain a first active compound and another plurality of particles may contain a second, different, active compound. The particles may be coated to provide different release profiles for each of the active
30 compounds in the dosage form. The coating for each of the pluralities of particles will typically be polymethacrylate materials of a composition and thickness to provide the desired release profile for each of the active compounds. Alternatively, one plurality of

particles may be coated with a different coating material from the other plurality, in order to take advantage of a differing release characteristic of a coating material other than a polymethacrylate.

5

The pluralities of particles in any such dosage form will typically be administered in an enterically coated capsule.

10 The invention will now be illustrated by the following non-limiting Examples with reference to the accompanying Figures.

Figure 1 is a graph of percentage release (%
15 Release), of prednisolone metasulphobenzoate from pellets coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to a theoretical weight gain of 5%, 15% and 25%, against time;

20

Figure 2 is a graph of percentage release (%
Release), of prednisolone metasulphobenzoate from pellets coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free
25 carboxyl groups to ester groups of 1:2 to a theoretical weight gain of 15%, against time at a pH of 6.0, 6.2, 6.6 and 7.2;

Figure 3 is a graph of percentage release (%
30 Release), of prednisolone metasulphobenzoate from pellets coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to a theoretical weight gain of 15% and a particle size of up to 1500 μm

and of up to 2000 μm , and pellets coated with a mixed polymethacrylate coating of 5% of a methacrylic acid ethyl acrylate copolymer with a ratio of free carboxyl groups to ester groups of 1:1 and 95% of a copolymer of
5 methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to 15% weight gain, against time;

Figure 4 is a graph of percentage release (%
10 Release), of paracetamol from pellets coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to a theoretical weight gain of 20%, against time at a pH of 6.2, 6.6 and 7.2;

15

Figure 5 is a graph of percent release (% release), of metronidazole from pellets coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to
20 ester groups of 1:2 to a theoretical weight gain of 20%, against time at a pH of 6.0, 6.6 and 7.2;

Figure 6 is a graph of percent release (% release), of metronidazole from pellets coated with a methacrylic
25 acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to a theoretical weight gain of 15%, 20% and 25% against time at a pH of 6.6; and

30 Figure 7 is a graph depicting how the activity of amylase, released from α -amylase pellets coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to

ester groups of 1:2 to a theoretical weight gain of 15%, 20% and 25%, varies against time at a pH of 6.0.

Example 1

5

Prednisolone metasulphobenzoate pellets were prepared by preparing a dry mix of 5 wt% prednisolone sodium metasulphobenzoate, 40 wt% microcrystalline cellulose (Avicel™ PH 101), 35 wt% lactose monohydrate (D80 200 Mesh) and 30 wt% croscarmellose sodium (Ac-Di-Sol™). Purified water (185 wt%) was added and the resulting mixture mixed for 10 minutes to form and extrudable paste which was then extruded from a 25 mm diameter bowel through a 1 mm diameter tube of about 5 mm length at a rate of about 100 mm/min, using a Niro Fielder Type E140 extruder, and spheronised in a Nica System Spheroniser S700 on a 20 cm plate rotated at about 33 rpm. The pellets were then dried in a fluid bed granulator and screened to ensure the size of the particles was in the range 800 to 1500 µm.

The pellets were then spray coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to provide three batches having a theoretical weight gain on coating (weight gain) of 5%, 15% and 25%.

The rate of release of prednisolone metasulphobenzoate from pellets having different thicknesses of coating and at a range of pH values was investigated.

Example 2

The effect on the rate of release of prednisolone metasulphobenzoate from pellets having a coating of 5%, 15% and 25% weight gain, prepared as described in Example 1, was studied in a dissolution apparatus by stirring the pellets in a tribasic sodium phosphate medium at pH 6 and withdrawing samples at 15 minute intervals to measure, by HPLC, the amount of prednisolone metasulphobenzoate in solution. The results are shown in Figure 1.

As can be seen from Figure 1, increasing the thickness of the coating significantly decreases the rate of drug release. The 5% weight gain coated pellets provide complete (100%) drug release within 15 minutes. The 15% weight gain coated pellets, however, provided 50% drug release after about 45 minutes and 100% drug release after about 100 minutes and the 25% weight gain coated pellets provided 50% drug release after 120 minutes and 100% drug release after about 300 minutes.

It is particularly surprising that particles coated with the same pH dissolution dependent coating material, but at different thicknesses, provide drug release as such significantly different rates at the same pH.

Example 3

The effect of pH on the rate of drug release from a coated pellet having a 15% weight gain coating prepared according to Example 1 was investigated. The pellets were subjected to drug release studies as described in Example 2 only using a pH of 6.0, 6.2, 6.6 and 7.2. Figure 2 illustrates the pH dependent nature of drug

release from coated pellets having a 15% weight gain coating.

As can be seen from Figure 2, at pH 6, complete drug
5 release occurs at about 120 minutes, with 50% drug
release at about 45 minutes. At higher pH, the rate of
drug release increases until at pH 7.2, complete drug
release occurs after about 30 minutes.

10 Example 4

In order to investigate the effect of the precise
coating composition on drug release, two batches of
prednisolone metasulphobenzoate pellets having a 15%
15 weight gain of either of two selected polymethacrylate
coating materials were prepared by the method of Example
1. Pellets of the first batch were coated with a mixed
polymethacrylate coating of 5% of a methacrylic acid
ethyl acrylate copolymer with a ratio of free carboxyl
20 groups to ester groups of 1:1 and 95% of a copolymer of
methacrylic acid and methyl methacrylate having a ratio
of free carboxyl groups to ester groups of 1:2 to 15%
weight gain. Pellets of the second batch were coated
with a copolymer of methacrylic acid and methyl
25 methacrylate having a ratio of free carboxyl groups to
ester groups of 1:2 to a weight gain of 15%.

The effect of coating composition on drug release
was investigated by subjecting the two batches of pellets
30 to a drug release study of the type described in Example
2. The results are illustrated in Figure 3.

As can be seen from Figure 3, batch 1, of which
pellets are coated with a mixture of polymethacrylates -

one which dissolves at pH 6.0 and one which dissolves at pH 5.5 - released drug at a greater rate than batch 2, of which pellets were coated with a polymethacrylate which dissolves at pH 6.0 to 7.0.

5

Example 5

In order to investigate the effect of pellet size on drug release, prednisolone metasulphobenzoate pellets
10 were prepared in two batches using the method of Example 1; the first batch having a diameter of up to 2000 μm and the second of up to 1500 μm and both having a coating of a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of
15 1:2 to a weight gain of 15%. The pellets were subjected to a drug release study as per Example 4. The results of this are also shown in Figure 3.

As Figure 3 shows, increasing the pellet size
20 resulted in a decrease in the rate of drug release. It is likely that this is because a larger pellet having a particular percentage weight gain of coating has a thicker coat than a smaller pellet with the same percentage weight gain of coating, because the ratio of
25 surface area to weight is lower for the larger pellet.

Example 6

Pellets containing paracetamol instead of
30 prednisolone metasulphobenzoate were prepared to a method corresponding to that of Example 1 and coated with a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to a weight gain of 20% and subjected to a drug

release study similar to that of Example 3, only at a pH of 6.2, 6.6 and 7.2. The results are illustrated in Figure 4.

5 As can be seen from Figure 4, the rate of drug release appears to be pH dependent in that at pH 6.2, 50% of the drug is released at 120 minutes and complete drug release occurs at about 300 minutes whereas at pH 7.2, there is complete drug release within 15 minutes.

10

Accordingly, the ability to control the delay and rate of drug release is not limited to prednisolone metasulphobenzoate, but clearly can be more broadly applied.

15

Example 7

Metronidazole pellets were prepared using the process as described in Example 1 with the exception that
20 20 wt % metronidazole was used in place of 5 wt % prednisolone metasulphobenzoate. The proportions of the remaining components were adjusted to 40 wt% microcrystalline cellulose (Avicel™ PH 101), 20 wt% lactose monohydrate and 20 wt% croscarmellose sodium (Ac-Di-Sol™).
25

The metronidazole pellets were then spray coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl
30 groups to ester groups of 1:2 to provide coated pellets having a theoretical weight gain on coating (weight gain) of 20%.

The effect of pH on the rate of release of metronidazole from the metronidazole pellets was studied in a dissolution apparatus by stirring the pellets in a tribasic sodium phosphate medium at pH 6.0, pH 6.6 and
5 then at pH 7.2 and withdrawing samples at 15 minute intervals to measure, by HPLC, the amount of metronidazole in solution. The results are shown in Figure 5.

10 As can be seen from Figure 5, at pH 6.0, complete drug release occurs at about 240 minutes, with 50% drug release at about 145 minutes. At higher pH, the rate of drug release increases until, at pH 7.2, complete drug release occurs after about 180 minutes.

15

Example 8

Metronidazole pellets were prepared as described in Example 7. The pellets were then spray coated with a
20 methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to provide three batches having a theoretical weight gain on coating (weight gain) of 15%, 20% and 25%.

25

The effect of coating thickness on the rate of release of metronidazole from the coated metronidazole pellets was studied in a dissolution apparatus by stirring each batch of pellets in a tribasic sodium
30 phosphate medium at pH 6.6 and withdrawing samples at 15 minute intervals to measure, by HPLC, the amount of metronidazole in solution. The results are shown in Figure 6.

As can be seen from Figure 6, increasing the thickness of the coating significantly decreases the rate of drug release. The 15% weight gain coated pellets provide complete (100%) drug release at about 120 minutes. The 20% weight gain coated pellets, however, provided 50% drug release after about 120 minutes and 100% drug release after about 240 minutes and the 25% weight gain coated pellets provided 50% drug release after about 200 minutes and 100% drug release after about 300 minutes.

Example 9

α -Amylase pellets were prepared using the process as described in Example 1 with the exception that the α -amylase was dissolved in the granulation fluid (water). The proportions of the other components were 40 wt% microcrystalline cellulose (Avicel™ PH 101), 20 wt% lactose monohydrate and 40 wt% croscarmellose sodium (Ac-Di-Sol™).

The pellets were then spray coated with a methacrylic acid copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of 1:2 to provide three batches having a theoretical weight gain on coating (weight gain) of 15%, 20% and 25%.

The effect of coating thickness on the rate of release of α -amylase from the coated α -amylase pellets at pH 6.0 was studied by colourimetry using the Sigma Enzymatic Assay of α -Amylase (EC 3.2.1.1) (Sigma-Aldrich Company Ltd., The Old Brickyard, New Road, Gillingham,

Dorset, SP8 4XT, UK) and the results are shown in Figure 7.

As can be seen from Figure 7, as with the
5 prednisolone metasulphobenzoate pellets and the
metronidazole pellets, increasing the thickness of the
coating significantly decreases the rate of drug release.
The amount of release of the α -amylase is directly
proportional to the activity observed. The 15% weight
10 gain coated pellets provided maximum amylase activity at
about 240 minutes. The 20% weight gain coated pellets,
however, provided about 50% total activity after about
180 minutes and 100% total activity after about 300
minutes. The 25% weight gain coated pellets provided 25%
15 total activity after about 180 minutes but, after 300
minutes, less than 50% total activity was observed.

The results of Examples 6 to 9 demonstrate that the
invention is applicable to active compounds other than
20 prednisolone metasulphobenzoate. The scope of
application of the invention is therefore surprisingly
broad.

It will be appreciated that the invention is not
25 restricted to the details described above with reference
to the preferred embodiments but that numerous
modifications and variations can be made without
departing from the spirit or scope of the invention as
defined by the following claims.

CLAIMS

1. An oral pharmaceutical composition comprising two or more pluralities of particles, said particles comprising
5 prednisolone metasulphobenzoate, wherein the particles of each said plurality are coated with a different thickness of a polymethacrylate material to those of the or each other plurality, whereby prednisolone metasulphobenzoate is released at different locations in the intestinal
10 tract.
2. A composition as claimed in Claim 1, wherein the polymethacrylate material is a pH dissolution dependent
15 polymethacrylate material.
3. A composition as claimed in Claim 1 or Claim 2, wherein each of said pluralities of particles is coated with a different thickness of the polymethacrylate material, whereby prednisolone metasulphobenzoate is
20 released at locations before and after the ileo-caecal valve.
4. A composition as claimed in any of Claims 1 to 3, wherein the thickness of polymethacrylate material
25 coating particles of each plurality of particles is of increments chosen to provide a homogeneous release profile of prednisolone metasulphobenzoate along at least one selected portion of the intestinal tract.
- 30 5. An oral pharmaceutical composition comprising two or more pluralities of particles, said particles comprising an active compound, wherein the particles of each said plurality are coated with a different thickness of a pH dissolution dependent polymethacrylate material to those

of the or each other plurality, whereby the active compound is released at different locations in the intestinal tract.

- 5 6. A composition as claimed in Claim 5, wherein the active compound is selected from the group consisting of prednisolone metasulphobenzoate, metronidazole and alpha-amylase.
- 10 7. A composition as claimed in any of the preceding claims, wherein the particles of each plurality are coated with the same coating material as those of the or each other plurality.
- 15 8. A composition as claimed in any of the preceding claims, wherein the polymethacrylate material comprises a methacrylic acid copolymer.
- 20 9. A composition as claimed in any of the preceding claims, wherein the polymethacrylate material comprises a copolymer of methacrylic acid and methyl methacrylate.
- 25 10. A composition as claimed in any of the preceding claims, wherein the polymethacrylate material is selected from a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of about 1:2, a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of about 1:1 or a mixture thereof.
- 30 11. A composition as claimed in any of the preceding claims, wherein the particles are coated with a methacrylic acid copolymer of methacrylic acid and methyl

methacrylate having a ratio of free carboxyl groups to ester groups of about 1:2.

12. A composition as claimed in any of the preceding
5 claims, wherein the particle has a diameter in the range 800 to 1500µm.

13. A composition as claimed in any of the preceding
claims, wherein the particles are coated with the
10 polymethacrylate material to a theoretical weight gain on coating in the range 5% to 30%.

14. A composition as claimed in any of the preceding
claims, wherein the particles are coated with the
15 polymethacrylate material to a theoretical weight gain on coating in the range 10% to 25%.

15. A composition as claimed in any of the preceding
claims, wherein the thickness of polymethacrylate
20 material coating particles of each plurality of particles is of increments chosen to provide a homogeneous release profile of the active compound along at least one selected portion of the intestinal tract.

25 16. A composition as claimed in any of the preceding claims, further comprising an enterically coated capsule within which the pluralities of particles are contained.

17. A composition as claimed in any of the preceding
30 claims, wherein there are two pluralities of particles.

18. A composition as claimed in any of the preceding
claims, wherein a first plurality of particles is coated
to provide a theoretical weight gain of 15% and a second

plurality of particles is coated to provide a theoretical weight gain of 20%.

19. A composition as claimed in Claim 17 and Claim 18,
5 wherein the first and second pluralities of particles are present in a ratio of about 1:3.

20. Use of the coating thickness of a pH dissolution dependent coating material on particles comprising an
10 active compound to control the release profile of the active compound in the intestinal tract.

21. A use as claimed in Claim 20, wherein the coating material is a polymethacrylate material.

15

22. A use as claimed in Claim 21, wherein the polymethacrylate material comprises a methacrylic acid copolymer.

20 23. A use as claimed in Claim 22 or Claim 23, wherein the polymethacrylate material comprises a copolymer of methacrylic acid and methyl methacrylate.

24. A use as claimed in any of Claims 20 to 23, wherein
25 the polymethacrylate material is selected from a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to ester groups of about 1:2, a copolymer of methacrylic acid and methyl methacrylate having a ratio of free carboxyl groups to
30 ester groups of about 1:1 or a mixture thereof.

25. The use as claimed in any of Claims 20 to 24 wherein the active compound is selected from the group consisting

of prednisolone metasulphobenzoate, metronidazole and
alpha-amylase.

26. An oral composition as defined in any of Claims 1 to
5 19 for use in therapy or diagnosis practised on the human
or animal body.

27. Use of a coating material selected from:

10 A. a polymethacrylate material; and

B. a pH dissolution dependent coating material

in the preparation of a medicament as defined in any of
15 Claims 1 to 19 for the treatment of disorders of the
intestinal tract.

28. A use as claimed in Claim 27, wherein the coating
material is a polymethacrylate material.

20

29. A use as claimed in Claim 27 or Claim 28, wherein
the coating material is a pH dissolution dependent
polymethacrylate material.

25 30. Use of a polymethacrylate material in the
preparation of a medicament as defined in any of Claims 1
to 19 for the treatment of Crohn's disease.

31. A method of treating a disorder of the intestinal
30 tract of a patient, said method comprising administering
to a patient an effective amount of an active compound
for treating that disorder in at least two pluralities of
particles each coated with a different thickness of a
coating material selected from

A. polymethacrylate material; and

B. a pH dissolution dependent coating material

5

to release the active compound at locations in the intestinal tract at which symptoms of the disorder are displayed.

10 32. A method as claimed in Claim 31 wherein the disorder is Crohn's disease.

33. A method as claimed in Claim 31 or Claim 32 wherein there are two pluralities of particles.

15

34. A method as claimed in any of Claims 31 to 33 wherein the active compound is prednisolone metasulphobenzoate.

20 35. A method as claimed in any of Claims 31 to 34 wherein the coating material is polymethacrylate material.

36. A method as claimed in any of Claims 31 to 35
25 wherein the active compound is released at locations before and after the ileo-caecal valve.

37. A composition substantially as hereinbefore described with reference to the accompanying Examples.

30

38. A use of the coating thickness of a pH dissolution dependent coating material substantially as hereinbefore described with reference to the accompanying Examples.

39. A use of a coating material substantially as
hereinbefore described with reference to the Examples.

FIGURE 1




FIGURE 2




FIGURE 3





FIGURE 4






FIGURE 5




FIGURE 6




FIGURE 7

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 03/02911

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 260 069 A (CHIH-MING CHEN) 9 November 1993 (1993-11-09)	5,7-15, 17, 20-24,26
Y	claims 1,2 column 3; example 1	1-4,6, 16,25, 27-39
X	US 5 834 024 A (GRANT WAYNE HEINICKE; ET AL.) 10 November 1998 (1998-11-10) claim 1 column 5, line 24 - line 32 -/-	5,7-15, 17, 20-24,26

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

C document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

14 October 2003

Date of mailing of the international search report

27/10/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/02911

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 267 990 B1 (WILFRIED FISCHER; ET AL.) 31 July 2001 (2001-07-31) claim 1 column 3; examples 1-4 ---	5,7-15, 17, 20-24,26
Y	US 5 834 021 A (CHRISTOPHER J. SPEIRS) 10 November 1998 (1998-11-10) claims 1,7,8 column 6; examples 1,4,5 ---	1-4,6, 16,25, 27-39
A	WO 97 02020 A (BYK GULDEN LOMBERG) 23 January 1997 (1997-01-23) the whole document -----	1-39

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 03/02911

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 31-36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/02911

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5260069	A	09-11-1993	AT 206613 T	15-10-2001
			AU 680642 B2	07-08-1997
			AU 5549294 A	22-06-1994
			CA 2149152 A1	09-06-1994
			DE 69330910 D1	15-11-2001
			DE 69330910 T2	04-04-2002
			EP 0670718 A1	13-09-1995
			ES 2165869 T3	01-04-2002
			JP 8506802 T	23-07-1996
			NZ 258012 A	28-10-1996
			WO 9412160 A1	09-06-1994
			US 5472708 A	05-12-1995
US 5834024	A	10-11-1998	US 6033687 A	07-03-2000
			US 6214385 B1	10-04-2001
US 6267990	B1	31-07-2001	DE 19724696 A1	24-12-1998
			AU 736357 B2	26-07-2001
			AU 8336898 A	30-12-1998
			CN 1260714 T	19-07-2000
			WO 9856355 A1	17-12-1998
			EP 0994696 A1	26-04-2000
			HU 0002719 A2	28-12-2000
			JP 2002504108 T	05-02-2002
			NO 996049 A	07-02-2000
			NZ 501726 A	28-09-2001
			PL 337279 A1	14-08-2000
			SK 169999 A3	11-07-2000
			TR 9903069 T2	22-05-2000
			ZA 9805142 A	12-01-2000
US 5834021	A	10-11-1998	GB 2292079 A	14-02-1996
			CA 2229283 A1	22-02-1996
			DE 69519577 D1	11-01-2001
			DE 69519577 T2	09-08-2001
			DK 772443 T3	19-02-2001
			EP 0772443 A1	14-05-1997
			WO 9604918 A1	22-02-1996
WO 9702020	A	23-01-1997	US 5945124 A	31-08-1999
			AT 232090 T	15-02-2003
			AU 6517496 A	05-02-1997
			CA 2232450 A1	23-01-1997
			DE 69626116 D1	13-03-2003
			DK 841903 T3	19-05-2003
			WO 9702020 A1	23-01-1997
			EP 1213015 A1	12-06-2002
			EP 0841903 A1	20-05-1998
			HK 1010836 A1	27-06-2003
			JP 11508577 T	27-07-1999
			PT 841903 T	30-06-2003
			SI 841903 T1	31-08-2003
			US 6068856 A	30-05-2000
			US 6274173 B1	14-08-2001